your market intelligence analyst
Search Results
Edit Save
1,990 results
Annals of Oncology 07/01/2019 20:00
Background: There has been no UK epidemiological data for cholangiocarcinoma (CCA) since 2008 when the incidence was reportedly 1-2 per 100,000 1 . Cancer data from many western countries have shown that the incidence and mortality rates of CCAs have been increasing 2 , 3 , with differing trends between subtypes; rising rates of intrahepatic cholangiocarcinoma (iCCA, ICD10 C22.1) and declining extrahepatic cholangiocarcinoma (eCCA, ICD10 C24.0).
Annals of Oncology 07/01/2019 20:00
Introduction: This trial evaluated activity and safety of mFOLFOXIRI + panitumumab vs FOLFOXIRI in ECOG 0-1, primarily non-resectable mCRC patients. The primary endpoint was initially presented at ASCO and ESMO 2018. Now we report the final results including central radiology review.
Annals of Oncology 07/01/2019 20:00
Introduction: Many patients with early-stage hepatocellular carcinoma (HCC) undergo hepatic resection and ablation as the standard of care, but while potentially curative, the risk of cancer recurrence following resection is as high as 44-79% at 5 years (Bruix and Sherman 2005, Imamura, et al 2003, Kianmanesh et al 2003).
Annals of Oncology 07/01/2019 20:00
Introduction: In Georgia, for resectable gastric cancer, the standard of treatment is neoadjuvant chemotherapy. Until 2017 before FLOT-4 results were presented, we used different chemotherapy regimens (ECX, EOX, DCX, FLOX). The aim of this trial is to compare FLOT vs other regimens in the neoadjuvant setting. This is the first study of neoadjuvant therapy in gastric cancer in a Georgian population. The primary endpoints of this study are pathologic and radiologic response rates of treatment. The secondary endpoints are surgical complications and toxicity of the treatment.
Annals of Oncology 07/01/2019 20:00
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease accounting as the fourth leading cause of cancer-related deaths worldwide. Surgical tumor resection is still the only hope for these pts to achieve long-term survival. Chemotherapy is the cornerstone of advanced PDAC treatment even if patient outcomes have been disappointing with this approach because of the occurrence of chemoresistance. Immunotherapy has shown to be unsuccessful in PDAC patients. It is uniquely characterized by multiple barriers to immunotherapy, and effective therapies likely will require combination approaches with current standard treatment. There have been several studies suggesting that the immune function status in patients who undergo ca.
Annals of Oncology 07/01/2019 20:00
Introduction: Clinical care of Pancreatic Ductal Adenocarcinoma (PDAC) in the real world is poorly understood. The aims of the GARIBALDI Study is to describe the current therapeutic management for naïve patients with PDAC undergoing either first treatment or clinical observation and to evaluate its consistency with Italian national recommendations provided by the Italian Association of Medical Oncology (AIOM 2017). A secondary aim is to describe the Overall Survival (OS), Disease-Free Survival (DFS) and Progression-Free Survival (PFS) of patients.
Annals of Oncology 07/01/2019 20:00
Introduction: Liver cancer ranks second worldwide in cancer-related deaths, advocating for more efficacious therapeutic strategies for hepatocellular carcinoma (HCC). Saikosaponin d (SSd), a natural compound and one of the most pharmacologically active saponin extracts from the root of Radix Bupleuri, holds promise as a new treatment for HCC. The aim of the study was to investigate the antitumorigenic effects of SSd, in two human hepatocellular carcinoma cell lines and define the signaling pathway of how SSd suppresses the expression of cyclooxygenase (COX)-2 in liver cancer.
Annals of Oncology 07/01/2019 20:00
Introduction: Colorectal cancer (CRC) is one of the most common cancers worldwide. In the last two decades, the incidence of CRC in Saudi Arabia has almost doubled. The majority of patients were older than 45. Understanding the association of clinical predictive features for systemic therapy outcome will help to guide treatment. The aim was to determine the outcome of metastatic CRC in relation to BMI, age and primary tumor site laterality, and to describe their influence on systemic therapy outcome of progression-free survival (PFS)
Annals of Oncology 07/01/2019 20:00
Introduction: Colorectal cancer (CRC) is a complicated and multifactorial disease with discrete genetic and epigenetic context. CRC begins as a growth called a polyp in the mucosal surface of the colon or rectum. It can invade the muscular layer of the colorectal wall and metastasizes to other parts of body and lymphatic system in advanced stages of colorectal cancer. CRC accounts for more than 9% of all cancer cases.
Annals of Oncology 07/01/2019 20:00
Introduction: Unresectable gastric cancer has an unfavorable prognosis with merely one year of median overall survival (OS) and the prognosis becomes even worse with peritoneal metastases. Recently, the efficacy data of intraperitoneal paclitaxel (ip PTX) in combination with systemic chemotherapy for gastric cancer with peritoneal metastases have been published. We have administered intraperitoneal therapy in 118 cases of gastric cancer. In this analysis we focus on cases resulting in successful conversion surgery.
Annals of Oncology 07/01/2019 20:00
Introduction: Preoperative chemo-radiotherapy followed by surgery has become the standard of care for resectable esophageal or GE junction tumors in most parts of the world since the publication of the CROSS trial in 2012. But leucopenia and cost of treatment are becoming issues with Paclitaxel-Carboplatin combination administered concomitantly with preoperative Radiotherapy. The present study aims to explore the efficacy and toxicity of concomitant Capecitabine for these patients. Major motivation behind this work was influenced by the successful role of concomitant Capecitabine in rectal and other GI cancers.
Annals of Oncology 07/01/2019 20:00
Introduction: The standard therapy for advanced adenocarcinoma of the esophagus and the gastroesophageal junction is a multimodal therapy concept. There are only a few randomized trials that have shown benefit from chemoradiation as compared to the neoadjuvant chemotherapy. In this retrospective single-center analysis, we analyzed all patients with esophageal cancer who received a multimodal therapy with neoadjuvant chemotherapy by FLOT-protocol or chemoradiation following the CROSS-protocol.
Annals of Oncology 07/01/2019 20:00
Introduction: In the worldwide clinical setting, the measurement of RAS-RAF mutations and microsatellite instabilities (MSI) for advanced and recurrent colorectal cancer (CRC) has been available and enables us to treat CRC patients with respect to genetic mutational profiles.
Annals of Oncology 07/01/2019 20:00
Introduction: To date, the standard of care for resectable PC pts is upfront radical surgery followed by adjuvant chemotherapy (CT). The role of CRT in this setting remains controversial and often it is reserved for PC pts with a high risk of local relapse, due to positive margins and/or positive lymph nodes.
Annals of Oncology 07/01/2019 20:00
Introduction: Pancreatic adenocarcinoma is the eighth leading tumor by incidence and third in mortality in Spain. Given the increasing incidence in patients under 65 years old with performance status (PS 0-1), the objective of the study was to describe epidemiological factors in this population, characteristics, and evolution with treatment.
Annals of Oncology 07/01/2019 20:00
Introduction: Current standard-of-care first-line treatments for metastatic pancreatic cancer (mPC) are associated with median progression-free survival (PFS) of approximately 6 months; the unmet need for effective and tolerable treatments in this setting is high.
Annals of Oncology 07/01/2019 20:00
Introduction: Colombia has recently improved from a lower-middle income country to an upper-middle income country1. Health disparities in gastric carcinoma (GC) survival have been described in cities and nations around the world, including Colombia2. A difference of up to 11% in overall survival (OS) regarding insurance status have been described in other cities in the nation3. However, this study does not consider the geographical localization as a health care access barrier, and there is a possible bias in analyzing OS of patients treated in multiples institutions with variable standards of care. In Colombia the health care system divides patients in contributory (pays the system for health care according to its salary) and subsidized (do.
Annals of Oncology 07/01/2019 20:00
Introduction: The mortality rate in pancreatic ductal adenocarcinoma (PDAC) is similar to its incidence rate due to the fact that almost 50% of the patients diagnosed have metastasis and 1-year OS for all stages barely over 20%. For this reason, new biomarkers (BKs) are urgently needed in order to improve outcomes in PDAC patients. Therefore, the main aim of this multicenter and prospective project is to find predictive and/or prognostic BKs. We will be focusing on CHFR (checkpoint with forkhead and ring finger domains) promoter methylation. This has been previously proposed as a predictor to taxane response in several tumors, even though its role in PDAC and/or in patients treated with nab-paclitaxel has not been described yet. On the othe.
Annals of Oncology 07/01/2019 20:00
Introduction: Radiofrequency ablation (RFA) had been considered a good option for small hepatocellular carcinoma (HCC) because of its minimal invasiveness. The aim of this study was to analyze the perioperative outcomes of laparoscopic liver resection (LLR) in HCC patients in comparison to percutaneous RFA.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications